Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

SMITH COUNTY, Texas (KLTV) - A Smith County jury sentenced a Longview parolee to 60 years in prison on drug charges. Wednesday ... 100 multicolored meth pills shaped like various superhero logos and ...

Hepatocellular carcinoma, the most common type of liver cancer ... drug Sotyktu for treating active psoriatic arthritis, marking a significant advancement in rheumatic conditions. It has also obtained ...

If approved, this combination therapy could provide a new first-line treatment option for patients with advanced liver cancer ... the combination of Opdivo (nivolumab) and Yervoy (ipilimumab ...

The company has successfully completed Phase 3 trials of its drug Sotyktu ... for the use of Opdivo and Yervoy as a first-line treatment for certain types of colorectal cancer.